HAVN Life Sciences Announces Completion of Acquisition Transaction

VANCOUVER, BC – HAVN Life Sciences Inc. (CSE: HAVN)  (“HAVN Life” or the “Company”) is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research”), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction”).  HAVN Research is a biotechnology company engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi.

Following completion of the Acquisition Transaction, the Company has 66,771,000 common shares in the capital of the Company issued and outstanding (the “Common Shares”). The Common Shares will be listed and posted on the Canadian Securities Exchange (the “CSE”), and are anticipated to commence trading at market open on September 8, 2020 under the stock symbol “HAVN”.

For further information, please contact:
HAVN Life Sciences Inc.
Email: ir@havnlife.com

Forward-Looking Statements Caution. This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including all statements in regard to the future plans or prospects of HAVN Research or the Company. The Company does not assume any obligation to update any forward-looking statements except as required under the applicable laws.

The CSE has not reviewed, approved or disapproved the content of this press release

‍